Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial
Background. Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need. Objective. The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-...
Gespeichert in:
| Veröffentlicht in: | Evidence-based complementary and alternative medicine 2017-01, Vol.2017 (2017), p.1-9 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | 2017 |
| container_start_page | 1 |
| container_title | Evidence-based complementary and alternative medicine |
| container_volume | 2017 |
| creator | Ko, Seong-Gyu Shin, Yong Cheol Kim, Mia Kang, Sohyeon Cho, Chong-Kwan Yoo, Hwa-Seung Yoo, Jeong-Eun Cheon, Chunhoo Jang, Bo-Hyoung |
| description | Background. Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need. Objective. The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-Quan-Da-Bu-Tang) for cancer-related anorexia. Methods. A total of 32 participants with cancer anorexia were randomized to either Sipjeondaebo-tang group or placebo group. Participants were given 3 g of Sipjeondaebo-tang or placebo 3 times a day for 4 weeks. The primary outcome was a change in the Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes included Visual Analogue Scale (VAS) of anorexia, FAACT scale, and laboratory tests. Results. Anorexia and quality of life measured by FAACT and VAS were improved after 4 weeks of Sipjeondaebo-tang treatment. However, there was no significant difference between changes of Sipjeondaebo-tang group and placebo group. Conclusions. Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer. Further large-scale studies are needed to ensure the efficacy. Trial Registration. This trial is registered with ClinicalTrials.gov NCT02468141. |
| doi_str_mv | 10.1155/2017/8780325 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5758845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A604313357</galeid><sourcerecordid>A604313357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-5fb2dfa9d54becf3e8c742a2bd15585fffe02bee9ffc8bfd4ed3c641ea79a1ec3</originalsourceid><addsrcrecordid>eNqNks-LEzEUxwdR3HX15lkCXgQ77iSTNBkPQq3rD1iwuBW8hTeZlzZLmtTM1LX-Cf7VprR21ZOnJOTDJ_m-94riMa1eUCrEOauoPFdSVTUTd4pTKjktOVPq7nEvv5wUD_r-uqpYI6W8X5ywhnNK6fi0-HlhrTNgtgRCR67A4rAl0ZIrt77GGDrANpZzCAtiYyKTEBN-d0BcIDMYHIahJzduWJIpBIPpJZmQmfNxGJFP2RdX7gd2I_ImblqP5WvvQj7NPJiddRrDkKL32JF5cuAfFvcs-B4fHdaz4vPbi_n0fXn58d2H6eSyNLxphlLYlnUWmk7wFo2tURnJGbC2y9VQwlqLFWsRG2uNam3HsavNmFME2QBFU58Vr_be9aZdYWdyiARer5NbQdrqCE7_fRPcUi_iNy2kUIqLLHh2EKT4dYP9oFeuN-g9BIybXrNcaEZ5zWVGn_6DXsdNCjmepo0aU5U5cUstwKN2wcb8rtlJ9WRc8ZrWtdi5RnvKpNj3Ce3xy7TSu1HQu1HQh1HI-JM_Yx7h373PwPM9sMxtgRv3nzrMDFq4pangio_rX2I8xuM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1986182145</pqid></control><display><type>article</type><title>Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial</title><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Ko, Seong-Gyu ; Shin, Yong Cheol ; Kim, Mia ; Kang, Sohyeon ; Cho, Chong-Kwan ; Yoo, Hwa-Seung ; Yoo, Jeong-Eun ; Cheon, Chunhoo ; Jang, Bo-Hyoung</creator><contributor>Kismali, Gorkem</contributor><creatorcontrib>Ko, Seong-Gyu ; Shin, Yong Cheol ; Kim, Mia ; Kang, Sohyeon ; Cho, Chong-Kwan ; Yoo, Hwa-Seung ; Yoo, Jeong-Eun ; Cheon, Chunhoo ; Jang, Bo-Hyoung ; Kismali, Gorkem</creatorcontrib><description>Background. Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need. Objective. The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-Quan-Da-Bu-Tang) for cancer-related anorexia. Methods. A total of 32 participants with cancer anorexia were randomized to either Sipjeondaebo-tang group or placebo group. Participants were given 3 g of Sipjeondaebo-tang or placebo 3 times a day for 4 weeks. The primary outcome was a change in the Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes included Visual Analogue Scale (VAS) of anorexia, FAACT scale, and laboratory tests. Results. Anorexia and quality of life measured by FAACT and VAS were improved after 4 weeks of Sipjeondaebo-tang treatment. However, there was no significant difference between changes of Sipjeondaebo-tang group and placebo group. Conclusions. Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer. Further large-scale studies are needed to ensure the efficacy. Trial Registration. This trial is registered with ClinicalTrials.gov NCT02468141.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2017/8780325</identifier><identifier>PMID: 29441116</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Alternative medicine ; Anemia ; Anorexia ; Cachexia ; Cancer ; Cancer patients ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical trials ; Double-blind studies ; Drug dosages ; Evidence-based medicine ; Feasibility studies ; Good Manufacturing Practice ; Health aspects ; Hemodialysis ; Herbal medicine ; Hospitals ; Melanoma ; Mortality ; Pharmaceutical industry ; Placebo effect ; Quality of life ; Randomization ; South Korea ; Substance abuse treatment</subject><ispartof>Evidence-based complementary and alternative medicine, 2017-01, Vol.2017 (2017), p.1-9</ispartof><rights>Copyright © 2017 Chunhoo Cheon et al.</rights><rights>COPYRIGHT 2018 John Wiley & Sons, Inc.</rights><rights>Copyright © 2017 Chunhoo Cheon et al.; This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 Chunhoo Cheon et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-5fb2dfa9d54becf3e8c742a2bd15585fffe02bee9ffc8bfd4ed3c641ea79a1ec3</citedby><cites>FETCH-LOGICAL-c499t-5fb2dfa9d54becf3e8c742a2bd15585fffe02bee9ffc8bfd4ed3c641ea79a1ec3</cites><orcidid>0000-0002-7078-0079 ; 0000-0003-3738-3239 ; 0000-0002-2141-3483 ; 0000-0002-2345-430X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758845/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758845/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29441116$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kismali, Gorkem</contributor><creatorcontrib>Ko, Seong-Gyu</creatorcontrib><creatorcontrib>Shin, Yong Cheol</creatorcontrib><creatorcontrib>Kim, Mia</creatorcontrib><creatorcontrib>Kang, Sohyeon</creatorcontrib><creatorcontrib>Cho, Chong-Kwan</creatorcontrib><creatorcontrib>Yoo, Hwa-Seung</creatorcontrib><creatorcontrib>Yoo, Jeong-Eun</creatorcontrib><creatorcontrib>Cheon, Chunhoo</creatorcontrib><creatorcontrib>Jang, Bo-Hyoung</creatorcontrib><title>Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial</title><title>Evidence-based complementary and alternative medicine</title><addtitle>Evid Based Complement Alternat Med</addtitle><description>Background. Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need. Objective. The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-Quan-Da-Bu-Tang) for cancer-related anorexia. Methods. A total of 32 participants with cancer anorexia were randomized to either Sipjeondaebo-tang group or placebo group. Participants were given 3 g of Sipjeondaebo-tang or placebo 3 times a day for 4 weeks. The primary outcome was a change in the Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes included Visual Analogue Scale (VAS) of anorexia, FAACT scale, and laboratory tests. Results. Anorexia and quality of life measured by FAACT and VAS were improved after 4 weeks of Sipjeondaebo-tang treatment. However, there was no significant difference between changes of Sipjeondaebo-tang group and placebo group. Conclusions. Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer. Further large-scale studies are needed to ensure the efficacy. Trial Registration. This trial is registered with ClinicalTrials.gov NCT02468141.</description><subject>Alternative medicine</subject><subject>Anemia</subject><subject>Anorexia</subject><subject>Cachexia</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Double-blind studies</subject><subject>Drug dosages</subject><subject>Evidence-based medicine</subject><subject>Feasibility studies</subject><subject>Good Manufacturing Practice</subject><subject>Health aspects</subject><subject>Hemodialysis</subject><subject>Herbal medicine</subject><subject>Hospitals</subject><subject>Melanoma</subject><subject>Mortality</subject><subject>Pharmaceutical industry</subject><subject>Placebo effect</subject><subject>Quality of life</subject><subject>Randomization</subject><subject>South Korea</subject><subject>Substance abuse treatment</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNks-LEzEUxwdR3HX15lkCXgQ77iSTNBkPQq3rD1iwuBW8hTeZlzZLmtTM1LX-Cf7VprR21ZOnJOTDJ_m-94riMa1eUCrEOauoPFdSVTUTd4pTKjktOVPq7nEvv5wUD_r-uqpYI6W8X5ywhnNK6fi0-HlhrTNgtgRCR67A4rAl0ZIrt77GGDrANpZzCAtiYyKTEBN-d0BcIDMYHIahJzduWJIpBIPpJZmQmfNxGJFP2RdX7gd2I_ImblqP5WvvQj7NPJiddRrDkKL32JF5cuAfFvcs-B4fHdaz4vPbi_n0fXn58d2H6eSyNLxphlLYlnUWmk7wFo2tURnJGbC2y9VQwlqLFWsRG2uNam3HsavNmFME2QBFU58Vr_be9aZdYWdyiARer5NbQdrqCE7_fRPcUi_iNy2kUIqLLHh2EKT4dYP9oFeuN-g9BIybXrNcaEZ5zWVGn_6DXsdNCjmepo0aU5U5cUstwKN2wcb8rtlJ9WRc8ZrWtdi5RnvKpNj3Ce3xy7TSu1HQu1HQh1HI-JM_Yx7h373PwPM9sMxtgRv3nzrMDFq4pangio_rX2I8xuM</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Ko, Seong-Gyu</creator><creator>Shin, Yong Cheol</creator><creator>Kim, Mia</creator><creator>Kang, Sohyeon</creator><creator>Cho, Chong-Kwan</creator><creator>Yoo, Hwa-Seung</creator><creator>Yoo, Jeong-Eun</creator><creator>Cheon, Chunhoo</creator><creator>Jang, Bo-Hyoung</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7078-0079</orcidid><orcidid>https://orcid.org/0000-0003-3738-3239</orcidid><orcidid>https://orcid.org/0000-0002-2141-3483</orcidid><orcidid>https://orcid.org/0000-0002-2345-430X</orcidid></search><sort><creationdate>20170101</creationdate><title>Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial</title><author>Ko, Seong-Gyu ; Shin, Yong Cheol ; Kim, Mia ; Kang, Sohyeon ; Cho, Chong-Kwan ; Yoo, Hwa-Seung ; Yoo, Jeong-Eun ; Cheon, Chunhoo ; Jang, Bo-Hyoung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-5fb2dfa9d54becf3e8c742a2bd15585fffe02bee9ffc8bfd4ed3c641ea79a1ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alternative medicine</topic><topic>Anemia</topic><topic>Anorexia</topic><topic>Cachexia</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Double-blind studies</topic><topic>Drug dosages</topic><topic>Evidence-based medicine</topic><topic>Feasibility studies</topic><topic>Good Manufacturing Practice</topic><topic>Health aspects</topic><topic>Hemodialysis</topic><topic>Herbal medicine</topic><topic>Hospitals</topic><topic>Melanoma</topic><topic>Mortality</topic><topic>Pharmaceutical industry</topic><topic>Placebo effect</topic><topic>Quality of life</topic><topic>Randomization</topic><topic>South Korea</topic><topic>Substance abuse treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ko, Seong-Gyu</creatorcontrib><creatorcontrib>Shin, Yong Cheol</creatorcontrib><creatorcontrib>Kim, Mia</creatorcontrib><creatorcontrib>Kang, Sohyeon</creatorcontrib><creatorcontrib>Cho, Chong-Kwan</creatorcontrib><creatorcontrib>Yoo, Hwa-Seung</creatorcontrib><creatorcontrib>Yoo, Jeong-Eun</creatorcontrib><creatorcontrib>Cheon, Chunhoo</creatorcontrib><creatorcontrib>Jang, Bo-Hyoung</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ko, Seong-Gyu</au><au>Shin, Yong Cheol</au><au>Kim, Mia</au><au>Kang, Sohyeon</au><au>Cho, Chong-Kwan</au><au>Yoo, Hwa-Seung</au><au>Yoo, Jeong-Eun</au><au>Cheon, Chunhoo</au><au>Jang, Bo-Hyoung</au><au>Kismali, Gorkem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><addtitle>Evid Based Complement Alternat Med</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Background. Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need. Objective. The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-Quan-Da-Bu-Tang) for cancer-related anorexia. Methods. A total of 32 participants with cancer anorexia were randomized to either Sipjeondaebo-tang group or placebo group. Participants were given 3 g of Sipjeondaebo-tang or placebo 3 times a day for 4 weeks. The primary outcome was a change in the Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes included Visual Analogue Scale (VAS) of anorexia, FAACT scale, and laboratory tests. Results. Anorexia and quality of life measured by FAACT and VAS were improved after 4 weeks of Sipjeondaebo-tang treatment. However, there was no significant difference between changes of Sipjeondaebo-tang group and placebo group. Conclusions. Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer. Further large-scale studies are needed to ensure the efficacy. Trial Registration. This trial is registered with ClinicalTrials.gov NCT02468141.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>29441116</pmid><doi>10.1155/2017/8780325</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7078-0079</orcidid><orcidid>https://orcid.org/0000-0003-3738-3239</orcidid><orcidid>https://orcid.org/0000-0002-2141-3483</orcidid><orcidid>https://orcid.org/0000-0002-2345-430X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1741-427X |
| ispartof | Evidence-based complementary and alternative medicine, 2017-01, Vol.2017 (2017), p.1-9 |
| issn | 1741-427X 1741-4288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5758845 |
| source | Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Alternative medicine Anemia Anorexia Cachexia Cancer Cancer patients Cancer therapies Care and treatment Chemotherapy Clinical trials Double-blind studies Drug dosages Evidence-based medicine Feasibility studies Good Manufacturing Practice Health aspects Hemodialysis Herbal medicine Hospitals Melanoma Mortality Pharmaceutical industry Placebo effect Quality of life Randomization South Korea Substance abuse treatment |
| title | Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T01%3A05%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20Sipjeondaebo-Tang%20for%20Anorexia%20in%20Patients%20with%20Cancer:%20A%20Pilot,%20Randomized,%20Double-Blind,%20Placebo-Controlled%20Trial&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Ko,%20Seong-Gyu&rft.date=2017-01-01&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2017/8780325&rft_dat=%3Cgale_pubme%3EA604313357%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1986182145&rft_id=info:pmid/29441116&rft_galeid=A604313357&rfr_iscdi=true |